Dengue Literature Review

Bos2025 - Longitudinal Antibody Dynamics After Dengue

6 min read

Bos2025 - Longitudinal Antibody Dynamics After Dengue

Full citation: Bos S et al. (2025). Longitudinal antibody dynamics after primary and secondary dengue virus infection. medRxiv. doi: 10.1101/2025.08.11.25333449

Raw file: [[raw/Bos2025.pdf]]

PREPRINT — not peer reviewed. Findings should be treated as preliminary until published in a peer-reviewed journal.

Summary

Bos et al. characterise the kinetics of 84 dengue virus-specific antibody features — spanning isotype (IgA, IgG, IgM), IgG subclass (IgG1–4), antigen target (E protein, NS1), and cross-reactivity (type-specific vs. heterotypic) — in a Nicaraguan pediatric cohort followed at four post-infection timepoints: <1 month, 3 months, 6 months, and 18 months. The study distinguishes primary from secondary infection, and reports antibody trajectories that diverge substantially depending on antigen, isotype, and whether the antibody is type-specific or cross-reactive.

The central finding overturns a core assumption of the classical antibody-waning model: cross-reactive E protein IgG (XR E-IgG) does not wane in the 6–18 month post-infection window — it rises, with a calculated half-life of −2.13 years (indicating active growth rather than decay). This stands in sharp contrast to NS1-IgG, which wanes with a t½ of approximately 2.1 years. Among isotypes, IgA seropositivity remains near 100% at 18 months, IgM persists in roughly half of primary-infection patients, IgG3 shows substantial seropositivity at 18 months, and IgG4 rises over the long term.

Domain-level analysis of E protein reveals that antibodies targeting domains I and II (EDI/II) — the regions involved in viral dimerisation and fusion, and a target of cross-reactive rather than serotype-specific neutralising antibodies — drive the XR IgG rise. Antibodies targeting domain III (EDIII), the receptor-binding domain and a focus of serotype-specific neutralising responses, remain flat. This dissection of the antibody response by domain specificity has direct implications for understanding which antibody populations are expanding in the inter-infection window and which are contracting.

Study Design

  • Type: Longitudinal cohort
  • Sample size: n = 79 pediatric patients
  • Setting: Hospital Infantil Manuel de Jesús Rivera (HIMJR), Managua, Nicaragua; DENV-1 and DENV-3 circulating serotypes
  • Population: Children with laboratory-confirmed dengue; primary and secondary infection groups; followed at <1M, 3M, 6M, and 18M post-dengue
  • Antibody features measured: 84 total (isotype × subclass × antigen × cross-reactivity)

Key Findings

  • XR E-IgG rises 6–18M post-primary: Calculated t½ = −2.13 years (negative indicating growth), in contrast to type-specific responses which are more stable. This challenges the assumption that all dengue-specific antibodies wane monotonically in the inter-infection window.
  • NS1-IgG wanes: t½ ≈ 2.1 years in primary infection; similar waning trajectory in secondary infection. NS1 antibodies are predominantly type-specific and follow the classical decay model.
  • IgA seropositivity ≈ 100% at 18M (both type-specific and cross-reactive), indicating remarkably durable mucosal and systemic IgA responses.
  • IgM seropositivity ≈ 50% at 18M post-primary: Unusually durable IgM, substantially exceeding the standard expectation of IgM clearance within 3–6 months post-infection.
  • IgG3 seropositivity substantial at 18M: Relevant to FcγRIIIA engagement kinetics (IgG3 has ~5× higher FcγRIIIA affinity than IgG1 per Bruhns2009 - FcγR Specificity and Affinity for IgG Subclasses).
  • IgG4 rises long-term: Consistent with a chronic/repeated antigen stimulation pattern; IgG4 is typically induced by sustained antigen exposure (e.g., allergen immunotherapy), and its rise may reflect ongoing dengue antigen persistence or repeated subclinical exposures in an endemic setting.
  • Domain specificity: EDI/II-targeting cross-reactive IgG drives the rising trajectory; EDIII-targeting antibodies (more serotype-specific, more neutralising) remain flat. This implies the expanding antibody pool in the 6–18M window is enriched for cross-reactive, non-EDIII antibodies — the class most likely to mediate ADE in subsequent infection.
  • Secondary infection kinetics: Antibody responses in secondary infection show more compressed, attenuated kinetics at 18M compared to primary, consistent with a more rapidly resolved and less expansive memory re-activation.

Methods Used

Entities Mentioned

Concepts Addressed

Relevance & Notes

Bos2025 is the most detailed longitudinal antibody kinetics study in this wiki. Its primary contribution to the existing literature is the rising XR E-IgG trajectory — directly challenging the classical model in which all cross-reactive antibodies wane monotonically, eventually dipping below the neutralisation threshold and creating the ADE window. Instead, it suggests the cross-reactive EDI/II-targeting IgG is actively rising in the inter-infection period, potentially extending or even deepening the ADE risk window rather than passively opening it through waning.

The NS1-IgG waning trajectory (t½ ≈ 2.1 years) provides the first kinetic data in this wiki to contextualise the autoimmunity thread: Lin2006/Lin2011 establish that anti-NS1 antibodies cross-react with platelet and endothelial surface proteins. If NS1-IgG wanes with a ~2.1 year half-life, the NS1-mimicry component of cross-reactive autoantibodies is likely declining rapidly after acute infection — consistent with Wan2012’s “acute peak, months persistence” characterisation. This helps bridge Chatterjee2024’s 54.8% acute IIFA rate toward Garcia2009’s 23.1% at 2 years: the NS1-mimicry component of ANA likely declines with the NS1-IgG trajectory, leaving only the potentially more durable epitope-spreading component.

IgG3 persistence at 18M adds kinetic evidence that FcγRIIIA-mediated effector functions (highly sensitive to IgG3 — see Bruhns2009 - FcγR Specificity and Affinity for IgG Subclasses) may persist long after acute infection, supporting sustained IC-driven inflammatory signalling. This is indirectly relevant to Garcia2009’s finding of IC elevations and ANA at 2 years.

Limitations: This is a preprint and has not undergone peer review. The cohort is pediatric and exclusively Nicaraguan (DENV-1/DENV-3); generalisability to other age groups, geographic settings, and serotypes requires validation. The 84-feature antibody panel is observational — causal claims (e.g., that the rising XR E-IgG mediates ADE) cannot be established from these data alone.

Questions Raised

  • Does the rising XR E-IgG after primary infection translate into rising ADE efficiency — and can this be demonstrated in functional neutralisation/enhancement assays?
  • What is the mechanism of IgM persistence to 18 months? In established immunology, IgM is typically short-lived; long-lasting IgM suggests either long-lived IgM plasma cells or ongoing antigen stimulation. Could persistent dengue antigen in tissues (NS1 stored in glycocalyx?) be driving this?
  • Is the IgG4 rise a consequence of chronic antigen exposure (dengue antigen persistence), repeated subclinical exposures in the endemic setting, or a class-switching trajectory specific to flavivirus responses?
  • Does the NS1-IgG waning trajectory correlate with declining anti-platelet / anti-endothelial autoantibody titres — directly linking NS1-IgG waning to resolution of NS1-mimicry-derived autoimmune reactivity?

Sources Cited by This Paper (not in wiki)

  • Additional references to classical ADE model sources not yet ingested; see raw PDF for full reference list.

Graph View

Backlinks